Amgen Inc. (AMG.DE)
XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
At close: 05:44PM CEST
| Previous close | 257.85 |
| Open | 259.10 |
| Bid | 291.70 x 20000 |
| Ask | 292.35 x 9000 |
| Day's range | 289.55 - 298.55 |
| 52-week range | 196.60 - 306.00 |
| Volume | |
| Avg. volume | 564 |
| Market cap | 158.314B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 25.15 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 8.29 (3.22%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | N/A |
- Yahoo Finance
Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
- Barrons.com
These Stocks Moved the Most Today: Apple, Amgen, Expedia, Coinbase, Cloudflare, Fortinet, Live Nation, and More
Apple reports better-than-estimated earnings and expands its buyback program by $110 billion, Amgen ‘very encouraged’ by preliminary data from a trial of a weight-loss drug, and Expedia reduces its sales outlook for the year.
- Investor's Business Daily
Amgen Is 'Very Encouraged' With Its Obesity Drug. But Can It Take On Novo, Lilly Duopoly?
Amgen stock neared its record high Friday after the company said it's "very encouraged" with midstage test results for its obesity treatment.
© 2024 Yahoo. All rights reserved.